2026-04-18T06:15:43Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1649992025-12-05T04:24:18Zcom_2072_1057col_2072_478809col_2072_478917
RECERCAT
author
Darbà, Josep
author
Ascanio, Meritxell
author
Carvalho, Davide
author
Conde, Vasco
author
Pedersen, Kasper S.
2020-06-10T08:05:43Z2020-12-20T06:10:18Z2019-12-202020-06-10T08:05:43Z
Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine (glargine) U100 from a Portuguese healthcare perspective using data from SWITCH 1 & 2 trials. - - - Methods: A short-term model estimated cost-effectiveness of degludec versus glargine U100 in type 1 diabetes (T1DM) basal bolus (B/B) and type 2 diabetes (T2DM) basal oral therapy (BOT) patients. The model captured hypoglycaemia rates and insulin dosing. Clinical outcomes were obtained from SWITCH 1 & 2. Disutilities related to hypoglycaemic events and insulin, needles and blood glucose tests costs were also included. Benefits were measured in QALYs. One-way and probabilistic sensitivity analyses were conducted (...)
cc-by-nc-nd (c) Cortex - Publicacoes Tecnicas e Cientificas, 2019 http://creativecommons.org/licenses/by-nc-nd/3.0/es info:eu-repo/semantics/openAccess
Anàlisi cost-benefici
Salut pública
Diabetis
Insulina
Portugal
Cost effectiveness
Public health
Diabetes
Insulin
Portugal
Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials
info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion